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Abstract: Leishmania species are the causative agents of leishmaniasis, a neglected tropical 
disease. These parasitic protozoans are usually transmitted between vertebrate hosts by the bite of 
blood sucking female phlebotomine sand flies. This review focuses on the two parasites causing 
most human visceral leishmaniasis (VL), which leads to substantial health problems or death 
for up to 400,000 people per year. Except for travel cases, Leishmania donovani infections are 
restricted to the (sub-)tropics of Asia and Africa, where transmission is mostly anthroponotic, 
while Leishmania infantum occurs in the drier parts of Latin America as well as in the Mediter-
ranean climate regions of the Old World, with the domestic dog serving as the main reservoir 
host. The prevalence of VL caused by L. infantum has been declining where living standards have 
improved. In contrast, infections of L. donovani continue to cause VL epidemics in rural areas 
on the Indian subcontinent and in East Africa. The current review compares and contrasts these 
continental differences and suggests priorities for basic and applied research that might improve 
VL control. Transmission cycles, pathogenesis, diagnosis, treatment and prognosis, prevention 
(including vector control), surveillance, transmission modeling, and international control efforts 
are all reviewed. Most case detection is passive, and so routine surveillance does not usually 
permit accurate assessments of any changes in the incidence of VL. Also, it is not usually pos-
sible to estimate the human inoculation rate of parasites by the sand fly vectors because of the 
limitations of survey methods. Consequently, transmission modeling rarely passes beyond the 
proof of principle stage, and yet it is required to help develop risk factor analysis for control 
programs. Anthroponotic VL should be susceptible to elimination by rapid case detection and 
treatment combined with local vector control, and one of the most important interventions may 
well be socioeconomic development.
Keywords: diagnosis, Leishmania donovani, Leishmania infantum, surveillance, transmission 
control, treatment
Introduction
Parasites, vectors, and disease forms 
Species of the genus Leishmania (Kinetoplastida, Trypanosomatidae) are the causative 
organisms of leishmaniasis or leishmaniosis,1 and these parasitic unicellular proto-
zoans are usually transmitted between vertebrate hosts by the bite of blood sucking 
female phlebotomine sand flies (Diptera, Psychodidae).2 Parasites of the subgenus 
 Sauroleishmania are considered to be restricted to lizards, and most lizard-feeding sand 
flies do not usually bite humans. About 20 species of Leishmania infect mammals and 
many of them can cause human leishmaniasis. Motile infective forms of the parasite 
(metacyclic promastigotes with a long free flagellum) develop in the guts of  competent 
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sand fly vectors, which inoculate them into mammalian 
skin. There they are ingested by cells of the mononuclear 
phagocyte system (formerly the  reticuloendothelial system), 
transform into rounded amastigote forms with the loss of the 
free flagellum, and then can multiply in the phagolysosomes 
of recruited macrophages to cause a primary lesion at the 
site of the sand fly bite. Infections can spread, often via the 
lymphatic system, to cause secondary dermal lesions with 
forms and tissue tropisms in humans that show some parasite 
species specificity. Human cutaneous leishmaniasis is caused 
by most Leishmania species in the subgenus Leishmania, 
which occur in most subtropical and tropical regions (for 
example Leishmania (Leishmania) major from Africa and 
Asia, and Leishmania (Leishmania) mexicana from Central 
and South America), and by many species in the subgenus 
Viannia, which are restricted to Latin America (for example 
 Leishmania (Viannia) brasiliensis). Any parasite causing cuta-
neous leishmaniasis can visceralize (for example  Leishmania 
(Leishmania) tropica, which normally causes Oriental sore), 
but only two species of the subgenus  Leishmania routinely do 
so, and these are the causative agents of most human visceral 
leishmaniasis (VL) worldwide.
Objectives
This review focuses on the two most important causative 
agents of VL, namely Leishmania (Leishmania) donovani and 
Leishmania (Leishmania) infantum, the ones responsible for 
causing substantial health problems in up to 400,000 people 
and up to 40,000 deaths per year.1,3 They are not always well 
distinguished in the medical literature, being closely-related 
members of the L. donovani species complex,4,5 but this dis-
guises some important epidemiological differences. Except 
for travel cases,1 L. donovani is found only in the Old World, 
where it is notoriously associated with VL (kala-azar or black 
death) of the rural poor in the northeast of the Indian subcon-
tinent and with VL of displaced persons in East Africa.1,6 Most 
transmission is believed to be anthroponotic, from human to 
human, and this contrasts with the zoonotic transmission of 
L. infantum, from canine reservoir hosts to humans, not only 
in the Mediterranean region where it may have originated, 
but also in many of the drier regions of Latin America where 
it was probably introduced historically.5
The incidence of VL associated with the transmission 
of L. infantum has been declining in many foci where living 
standards have improved; but, in contrast, VL epidemics 
continue to kill thousands of people infected with L. donovani 
on the Indian subcontinent and in East Africa. Therefore, the 
main aims of the current review are to compare and contrast 
these continental differences, and to suggest priorities for 
basic and applied research that might improve VL control. 
Leishmaniasis is a neglected tropical disease,1,6 and it is pos-
sible that the recent increases in the direct or indirect funding 
of applied research will not be sustained unless research 
priorities are well founded.1,2
Methods: literature search
This review is based on expert knowledge, wide-ranging 
reviews published in 2010–2013,1,2,6 and other, sometimes 
more recent, literature found in PubMed by using the search 
terms “visceral leishmaniasis”, “kala-azar”, “Leishmania 
donovani”, “Leishmania infantum”, and key words in the 
following section titles.
Transmission cycles: geographical  
variation in eco-epidemiology
The key elements are set out in Table 1. VL caused by 
L. donovani is usually considered to be an anthroponosis,2 
but this should be challenged where control fails. Zoonotic 
transmission has been suspected because parasites or cir-
culating antibodies have been detected in domestic animals 
on the Indian subcontinent7 and in the mongoose and other 
wild mammals in East Africa.1 The landscape  epidemiology 
is very different on the two continents.2 Phlebotomus 
(Euphlebotomus) argentipes is the vector in humid (sub-)
tropical regions on the Indian subcontinent, where it is 
attracted to domestic cattle and water buffalo kept in and 
around rural villages near the flood plain of the River 
Ganges, in Sri Lanka and perhaps in Bhutan.8 In contrast, 
Phlebotomus (Larroussius) orientalis and Phlebotomus 
(Synphlebotomus) species are the incriminated vectors in two 
distinctive bioclimatic regions of East Africa,2,9 which share a 
savanna landscape and transmission habitats both inside and 
outside rural villages. Most foci on the Indian subcontinent 
are in long-established villages with sedentary populations, 
whereas migratory populations are also at high risk in East 
Africa, including cattle herdsmen and villagers displaced by 
drought and warfare. Post-kala-azar dermal leishmaniasis 
(PKDL) is characterized by lesions rich in parasites, and 
these might favor anthroponotic transmission in Africa as 
well as in India.3
VL caused by L. infantum is usually considered to 
be a zoonosis, although congenital infections have been 
reported even in Europe.10 Most foci in the Old World 
have a  Mediterranean climate and sand fly vectors that can 
 hibernate – usually Phlebotomus (Larroussius) species – and 
so there is a risk of the disease spreading from southern 
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to northern Europe with climate change.2 All vectors of 
 Leishmania in the New World are Lutzomyia species, but 
only one of these is believed to be an important widespread 
vector of L. infantum. Diverse populations of Lutzomyia 
(Lutzomyia) longipalpis are abundant peridomestically 
in the yards of rural villages and the low-rise suburbs 
and shanty towns of many of the drier tropical regions of 
Latin America, and, unlike most sand fly species, they are 
competent to transmit a wide range of Leishmania species2 
including L. infantum. This parasite is believed to have been 
introduced in domestic dogs from Portugal and Spain during 
the last 500 years.5
Molecular taxonomy has not identified Leishmania 
archibaldi as a species separate from L. donovani in Africa 
or Leishmania chagasi as a species separate from L. infantum 
in Latin America, and the diverse groupings of the strains 
of L. donovani and L. infantum identified by neutral (or 
nonadaptive) genetic markers4,5 have not been associated 
with phenotypes of medical importance. Similarly, there 
is little or no evidence that the diverse forms of the vectors 
P. argentipes and Lu. longipalpis, identified as cryptic sibling 
species based on neutral genetic markers, have distinctive 
epidemiological roles.2
Pathogenesis
The incubation period is usually from 2 weeks to 18 months,11 
with gross inflammatory reactions within the viscera often 
developing 2–8 months after infection and any initial skin 
lesions, but VL symptoms can take years to appear.12 The 
disease is progressive and a symptomatic infection that 
is untreated is generally fatal,12 with a mortality rate of 
75%–95%.11 Death usually occurs within 2 years, although 
spontaneous cures may occur.11 Parasites proliferate wher-
ever there are cells of the mononuclear phagocyte system, 
most often in macrophages. These are most abundant in 
the spleen and liver and, consequently, infection leads to an 
enlargement of both of these organs.11–13 Bone marrow cells 
become infected, and patients develop pancytopenia (namely, 
depressed production of red blood cells, white cells, and 
platelets) and immunosuppression, making them susceptible 
to superinfections.11,13
PKDL or dermal leishmanoid11 is a condition in which 
dermal lesions can be heavily parasitized in a subset of 
patients successfully treated for VL, and it occurs mainly in 
India and Sudan in patients infected by L. donovani.13,14 They 
remain asymptomatic for months to years and then develop a 
progressive proliferation of parasites within the skin, giving 
rise to diffuse macular, maculopapular, or nodular lesions.13 
Lesions appear anywhere on the body, but they often occur 
on the face.12
Diagnosis
Clinical symptoms  
and microscopic diagnosis
Most infections are diagnosed clinically. The patient has an 
irregular fever, anemia, and leukopenia;  hepatosplenomegaly 
and bone marrow suppression are characteristic (see above); 
and HIV coinfections often produce atypical presenta-
tions.11–13 Rates of PKDL vary regionally, arising within 
6 months in up to 50% of treated VL patients in parts of 
Sudan, but within 2–3 years in only approximately 5%–10% 
of patients in India.12–14
Table 1 Disease types and transmission cycles of visceral leishmaniasis worldwide
Causative  
parasites
Disease Countries 
(suspected)
Landscapes Reservoir hosts Incriminated  
vectora
Suspected vectora
L. donovani vL, DL, CL Northeast india, Nepal,  
Bangladesh, (Bhutan),  
Sri Lanka
Rural, peri-domestic Human anthroponosis P. (Eu.)  
argentipes
None
L. donovani vL People’s Republic of China Rural, peri-domestic Unknown None P. (Pa.) alexandri; 
P. (Ad.) species
L. donovanib vL, DL Sudan, Ethiopia, (Chad),  
(Yemen)
Rural, Acacia– 
Balanites forest
Human anthroponosis;  
possibly mongoose?
P. (La.)  
orientalis
None
L. donovanib vL, DL Sudan, Ethiopia, Kenya,  
(Uganda)
Rural, savanna 
termite mounds
human anthroponosis? P. (Sy.) martini P. (Sy.) celiae, 
P. (Sy.) vansomerenae
L. infantum vL, CL Med Europe, North Africa,  
Southwest Asia, People’s 
Republic of China
Rural, peri-domestic Domestic dog, wild  
canids, domestic cat
P. (La.) ariasi, 
perniciosus
P. (La.) species; 
P.(Ad.) species
L. infantumc vL, CL Latin America: not Peru or  
Guianas
Rural, peri-domestic Domestic dog, wild  
canids
Lu. (L.) 
longipalpis
Lu. (Lu.) species; 
Lu. (Pf.) evansi
Notes: avectorial status based on number of criteria met;2 bsome strains formerly named L. archibaldi; csometimes named L. chagasi.
Abbreviations: Ad., Adlerius; CL, cutaneous leishmaniasis; DL, diffuse or dermal leishmanoid leishmaniasis; Eu., Euphlebotomus; L., Leishmania; La., Larroussius; Lu., Lutzomyia; 
Med, Mediterranean; P., Phlebotomus; Pa., Paraphlebotomus; Pf., Pifanomyia; Sy., Synphlebotomus; vL, visceral leishmaniasis.
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Parasites are usually identified to the genus Leishmania by 
light microscopy.11,12 The amastigote form is usually detected 
microscopically after Giemsa staining. Blood examinations 
are the easiest to perform, but frequently there are very few 
circulating parasitized cells in buffy coat films.11,12 Spleen 
aspirates are a rich source of parasites,11 but biopsy should 
be performed only by trained personnel because there 
is the risk of rupture or bleeding.12 Liver biopsy is safer, 
although finding amastigotes is certain only in very heavy 
infections.11,12 Bone marrow aspiration (from the sternum) 
is frequently used,11 but it is a specialized technique with 
lower sensitivity.12 Detection of parasites in nodular forms 
of PKDL is easier than in macular forms.13,14 Inoculation of 
biopsy materials into culture media or laboratory rodents can 
be sensitive but slow.1
Biochemical diagnosis
Until recently, isoenzyme analysis has been the gold-standard 
method to identify both phylogenetic species and strains 
(or zymodemes) of Leishmania, which usually reproduce 
asexually.1,5 However, it requires growing many parasites, 
and promastigote cultures can fail because of contaminating 
bacteria and fungi, or strain-specific temperature and nutrient 
requirements.
Serological diagnosis
Serological tests provide the most widely used indirect 
 methods of diagnosis.1 The indirect fluorescence antibody 
test, the enzyme-linked immunosorbent assay, and the West-
ern blot12 are widely used in Africa, Asia, Europe, and Latin 
America, but they all require equipment that has not been 
optimized for field conditions12 and there is often a lack of 
standardized protocols, antigens, and other reagents.15 The 
Montenegro or leishmanin skin test has the same drawbacks 
and may not even be specific to Leishmania species.1 It is 
negative in active kala-azar, and then usually becomes posi-
tive within 2 months after successful treatment.11
In contrast, two other types of tests have proved to have 
high sensitivity and specificity, at least regionally, and have 
translated to peripheral health centres.12,16 These are the direct 
agglutination test and immunochromatographic tests (ICTs) 
using the recombinant (r) K39 antigen, which is encoded by a 
fragment of a kinesin-related gene. The rK39 ICTs have the 
advantage of using convenient formats (often a dipstick) and 
a standardized recombinant antigen. However, the kinesin-
related gene fragment derives from a Brazilian strain of 
L. infantum, and the kinesin genetic diversity among strains 
of L. donovani in East Africa and between there and Asia is 
extensive enough to influence the performance of the rK39 
ICTs.17 Even in Brazil, the diagnostic performance of rK39 
ICTs was found to be only reasonable for confirmation of 
infection in suspected cases of canine VL, and the sensitivity 
to detect infected dogs was too low for large-scale epidemio-
logical studies and operational control programs.18
Serological tests have limitations because some antibod-
ies are detectable years after cure.12 A latex agglutination 
test detecting a heat-stable carbohydrate in the urine of VL 
patients has promise as a field-adapted antigen test; it showed 
good specificity but low-moderate sensitivity.19
Molecular diagnosis
The polymerase chain reaction is more sensitive than micro-
scopic examination and, therefore, it is often the primary test 
in referral hospitals and research centers, with quantitative 
polymerase chain reaction permitting accurate diagno-
sis using venous blood samples instead of bone marrow 
aspirates.12,16 Leishmania species and their strains causing 
VL can now be identified by the comparative DNA sequence 
analysis of five of the polymorphic metabolic enzymes rou-
tinely used for isoenzyme analysis,20 by restriction fragment 
length polymorphism analysis of the heat-shock 70 gene,21 
and by microsatellite DNA analysis.4
Conclusion: integrated diagnosis
Molecular tests in hospitals and research centers permit strain 
identification and diagnosis using venous blood samples. 
However, many primary health teams rely on clinical symp-
toms together with rK39 ICTs for rapid diagnosis prior to 
chemotherapy. A combination of molecular and serological 
tests demonstrated significant numbers of asymptomatic 
infections in endemic areas of Bihar State, India.16 The selec-
tion of the best combinations of rapid diagnostic tests might 
be improved by meta-analyses of Phase IV studies performed 
in target populations, and Bayesian methods could improve 
estimates of sensitivity and specificity.22
Treatment and prognosis
Travel cases, indigenous cases,  
and health care
Few travel cases of VL are usually recorded in North America 
and Europe,1,9,23 and a recent review alerts clinicians to the 
range of clinical syndromes, treatments, and prognoses, 
including the development of PKDL seen in patients with 
HIV/AIDS undergoing highly active antiretroviral therapy 
(HAART).13 Treatment and prognosis for indigenous cases 
are determined by regional health care practices and 
Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
151
visceral leishmaniasis
budgets, with fewer uncomplicated cases being resolved in 
East Africa and India than in southern Europe and Brazil.1,6 
Malnutrition is one of the important risk factors for VL, and 
a fall in disease incidence in southern Europe during the last 
50 years coincided with better nutrition.1,6
Drug resistance and alternatives 
to pentavalent antimonials
Much research is focused on the resistance mechanism 
to pentavalent antimonials, which have been the standard 
drugs despite their toxicity.12 They are now nearly obsolete 
in Bihar State, India, because of drug resistance, but sodium 
 stibogluconate (Pentostam [GlaxoSmithKline UK Ltd] and 
a generic brand) and meglumine antimoniate (Glucantime; 
Sanofi S.A., Paris, France) are useful elsewhere.
AmBisome (Gilead, Foster, CA, USA), a liposome 
formulation of amphotericin B, is now a standard treat-
ment for VL, especially against L. donovani in Bihar, and a 
single dose treatment has been successfully trialed in rural 
public hospitals in Bangladesh (http://www.who.int/tdr/
news/2013). However, clinical studies indicate that it is less 
effective against L. donovani in East Africa and L. infantum 
in Latin America and, therefore, further research is required.12 
 Similarly, paromomycin is  efficacious in the Indian subcon-
tinent, but not in East Africa.12  Miltefosine, a phospholipid 
derivative, provides an oral treatment for VL, and it has been 
used in the VL  Elimination Programme for the Indian Sub-
continent.12 However, it is potentially teratogenic, requires a 
long oral treatment (28 days) that can lead to poor compliance 
and relapses, and drug resistance is a concern.12
Novel drug combinations
Drug combinations can shorten therapy as well as reducing 
toxicities and the selection of resistant mutations, and so there 
have been some promising Phase III trials of combinations 
of AmBisome, miltefosine, and paromomycin in India and of 
sodium stibogluconate with paromomycin in Sudan.12 Barrett 
and Croft12 noted that new drugs might target parasites in the 
low pH phagolysosomes of macrophages.
Prevention
vaccine development
Vaccination is probably the best way of controlling a rural 
vector-borne disease like leishmaniasis.1,2,24 Unfortunately, 
no vaccine is likely to be deployed in the short-term against 
VL, partly because of the complexity of the cellular immune 
response and the immunomodulatory effects of antigens 
from sand fly saliva.1,2 Salivary peptides could also be 
vaccine components.2,24 Vaccines against canine leishma-
niasis have been trialed in Brazil and Europe with mixed 
results,1,10,18 and this could be an effective way of reducing 
the transmission of L. infantum to people.
vector control
Unlike for mosquitoes, source reduction is not an option 
because the terrestrial sites of sand fly larvae are largely 
unknown. The spraying of residual insecticides, often 
 dichlorodiphenyltrichloroethane (DDT), to control  Anopheles 
mosquitoes was a key component of the malaria eradication 
campaign of the mid-20th century, and it is credited with 
having greatly depressed the transmission of L. donovani in 
India and L. infantum in southern Europe by the untargeted 
killing of peri-domestic adult sand flies.1,25 VL resurgence 
followed the cessation of DDT spraying, but this could have 
been coincidental. Since then, a range of vector control 
approaches have been tested, but there is little evidence that 
the results of experimental trials have informed public health 
approaches.
Indoor residual spraying with DDT or pyrethroids has been 
the mainstay of VL vector control on the Indian subcontinent 
and in Brazil,1,25,26 but it is unknown whether or not the insec-
ticide reaches or remains for long on the surfaces favored by 
the adults of P. argentipes and Lu. longipalpis, many of which 
may spend more time on cattle or chickens, respectively, than 
on the inner or outer walls of houses and animal shelters.27,28 
Insecticide-treated (mosquito) nets have been tested on the 
Indian subcontinent and in East Africa,8 occasionally as long-
lasting insecticidal nets,26,29 and sometimes they have been 
shown to be better than indoor residual spraying for reducing 
the local abundance of vectors, as in Bangladesh.30 Little or no 
insecticide resistance has been detected in VL foci,1 and this is 
consistent with only a small fraction of the vector populations 
being exposed to insecticides.
Insecticidal sprays, roll-ons, and collars are widely used 
for protecting dogs in southern Europe and the wealthier 
areas of Latin America, but this may provide only individual 
 protection, not the community-wide control that would 
reduce transmission from dogs to humans.27 N, N-diethyl-
meta-toluamide (DEET) has been the repellent of choice 
for the individual protection of people, and cheaper natural 
products have started to be tested.2 Integrated control has 
occasionally identified avenues of applied research that 
should be further explored, including environmental modi-
fication by plastering the walls of village houses with mud 
or lime to reduce the number of sand fly resting sites in VL 
foci on the Indian subcontinent.25
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Surveillance, transmission  
modeling, risk factors, and  
predictive modeling
Routine surveillance is usually too insensitive to assess accu-
rately any changes in the prevalence or incidence of VL,15,27 
with most case detection being passive.6 Also, it is not usually 
possible to estimate the human inoculation rate of parasites by 
the sand fly vectors2 because most sand fly surveys use light 
and sticky traps that do not target  host-seeking female flies, 
and the reports often mention only the relative abundances 
of species without distinguishing males from females.25,26 
Consequently, transmission modeling is not commonplace, 
although research projects have provided proofs of principle 
models for VL transmission in Asia31 and for canine leishma-
niasis in Europe.32 Better transmission modeling is required 
to underpin risk factor analysis, which is more likely to be 
applied in control programs. Risk factor analysis has been 
carried out for foci on the Indian subcontinent,28 in Ethiopia,33 
and in Brazil,27 frequently identifying poverty, malnutrition, 
and proximity of parasite or vector hosts to dwellings as high 
risk factors. Spatial modeling has usually only predicted the 
presence or absence of disease and vectors based on rather 
broad measures of climate and environmental variation,2,15,32 
providing resolution that is little better than descriptive land-
scape epidemiology.
Prevalence and incidence
This topic is considered late in this review because it depends 
on an understanding of the different disease forms associated 
with geographically-isolated transmission cycles and regional 
differences in surveillance. The disease burden will strongly 
influence the regions chosen for sustainable integrated control 
of VL, which is discussed in the next section.
A major review of the incidence of leishmaniasis world-
wide was led by the World Health Organisation (WHO) 
Leishmaniasis Control Programme, and the findings were 
published in 2012.6 This review concluded that leishmaniasis 
had often been ignored in discussions of tropical disease 
priorities because of the paucity of current incidence data. 
Disease burden is often expressed as disability-adjusted 
life years, but the accuracy of this measure depends on the 
reliability of the incidence, duration, severity, and mortality 
data for a condition, which are difficult to extrapolate from 
official data sources because of the focal distribution of leish-
maniasis in remote locations.6 The 2012 review concluded 
that the majority of VL deaths are unrecorded, and case 
fatality rates may be 10%–20% even with treatment access. 
However, the authors did produce regional tables of reported 
and estimated VL incidence based on the expert opinions 
of national program managers and professionals;6 these are 
summarized in Table 2. Among the few published empirical 
Table 2 Reported and estimated incidence of vL worldwide
Region Country Reported cases 
per annum
Report years Estimated annual 
incidence
America Brazil 3,481 2003–2007 4,200–6,300
Others 187 2004–2008 300–500
Total 3,668 4,500–6,800
Mediterranean Spain, italy, Albania 365 2003–2008 440–660
Morocco, Algeria, Tunisia 352 2004–2008 540–970
Others 158 2002–2008 220–370
Total 875 1,200–2,000
East Africa Sudan 3,742 2005–2009 15,700–30,300
South Sudan 1,756 2004–2008 7,400–14,200
Ethiopia 1,860 2004–2008 3,700–7,400
Somalia 679 2009 1,400–2,700
Others 535 2004–2008 1,200–1,400
Total 8,569 29,400–56,000
Middle East to  
Central Asia
iraq 1,711 2004–2008 3,400–6,800
People’s Republic of China 378 2004–2008 760–1,500
Others 407 2004–2008 840–1,700
Total 2,496 5,000–10,000
indian subcontinent  
and Southeast Asia
india 34,918 2004–2008 146,700–282,800
Bangladesh 6,224 2004–2008 12,400–24,900
Nepal 1,477 2004–2008 3,000–5,900
Others 4 2005–2010 21–40
Total 42,623 162,121–313,640
Note: Alvar J, vélez iD, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.6
Abbreviation: vL, visceral leishmaniasis.
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assessments of under-reporting in surveillance data, two 
from Bihar, India, compared VL case numbers estimated by 
house-to-house surveys with official data, which were 4.2-
fold and 8.1-fold lower.6
The incidence of VL associated with the transmission 
of L. infantum by sand flies has been declining in many foci 
where living standards have improved, with better  nutrition 
believed to mitigate the progression of debilitating or fatal 
infantile visceral leishmaniasis.6 Also, there has been a 
decline or stabilization in the incidence of VL resulting 
from the transmission of L. infantum by needles or blood 
transfusion through better awareness and drugs to combat 
coinfecting HIV.6
International collaboration for 
sustainable integrated control of VL
The paradigm for controlling vector-borne diseases should 
be prevention at source using an integrated set of inter-
vention measures,34 not detection and response. There are 
many lessons to be learned from malaria control,35 includ-
ing the realization that the aim of sand fly control should 
not be to reduce the relative abundance of a vector species, 
but to reduce the contact of its blood feeding females with 
humans and to reduce their lifespans so that fewer survive 
long enough to transmit Leishmania parasites.
The VL Elimination Programme for the Indian  Subcontinent 
was set up as an international collaboration between Bangla-
desh, India, and Nepal in 2005.36 This required a clear set of 
aims and objectives, which prompted the standardization of 
experimental trials aided by European and North American 
researchers and funding  agencies. There continues to be a 
need to assess by appropriate randomized trials the efficacy of 
some of the common intervention tools, including the residual 
activity of insecticides on bednets.37
Conclusion: priorities for applied 
and basic research
It has been argued that leishmaniasis research has focused 
too much on descriptive eco-epidemiology at the expense 
of transmission modeling and integrated control.2 For 
example, it does not really matter whether the causative 
agents of VL are classified by molecular taxonomists as two 
species (L. donovani and L. infantum) or as four species 
(with L. archibaldi and L. chagasi also recognized), if these 
taxa are not associated with specific sets of symptoms, 
treatments, and interventions in each endemic region. It 
is surely more important to understand what determines 
the distributions of parasite phenotypes of importance for 
treatment and control within each regional anthroponosis 
or zoonosis. Basic research on drug resistance and devel-
opment underpins the applied aims of chemotherapy, but 
priorities are less clear for basic research for vector con-
trol and vaccine development. Predictive spatiotemporal 
modeling of VL should focus more on where and when 
disease incidence is likely to change, not on the presence or 
absence of species of parasites and vectors. A recent review 
of preventative measures against human leishmaniasis 
infection concluded that more research is needed to inves-
tigate human infection as the primary outcome measure, 
as opposed to intermediate surrogate markers.38
VL on the Indian subcontinent and in many African foci 
is believed to be an anthroponotic disease, and, therefore, it 
should be susceptible to elimination by rapid case  detection 
and treatment combined with local vector control. However 
diagnosis of early infections can be problematic.6,17,19 The 
economic cost benefits of control are being explored on both 
continents,39,40 and one of the most important interventions 
against VL may well be socioeconomic development, as 
it is for malaria.41 Applied research on leishmaniasis must 
continue to be prioritized in order to ensure that it continues 
to benefit directly or indirectly from the support of the Bill 
and Melinda Gates Foundation (http://www.gatesfoundation.
org), Drugs for Neglected Diseases initiative (http://www.
dndi.org), Médecins Sans Frontières (http://www.msf.org), 
TDR-World Health Organization (http://www.who.int/tdr), 
and other bodies. The combat against VL might be assisted 
by the proposal to combine groups already working on 
 chemotherapy into a single organization, the VL Global R&D 
and Access Initiative.42
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